| __timestamp | Alpine Immune Sciences, Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2287709 | 7890000 |
| Thursday, January 1, 2015 | 6844000 | 14456000 |
| Friday, January 1, 2016 | 8586000 | 19218000 |
| Sunday, January 1, 2017 | 6079000 | 27986000 |
| Monday, January 1, 2018 | 8362000 | 47928000 |
| Tuesday, January 1, 2019 | 9467000 | 96388000 |
| Wednesday, January 1, 2020 | 10899000 | 157743000 |
| Friday, January 1, 2021 | 14560000 | 195293000 |
| Saturday, January 1, 2022 | 17968000 | 237374000 |
| Sunday, January 1, 2023 | 22222000 | 295141000 |
| Monday, January 1, 2024 | 359272000 |
In pursuit of knowledge
In the dynamic world of biotechnology, operational efficiency is key to sustaining innovation. Over the past decade, Blueprint Medicines Corporation and Alpine Immune Sciences, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, reflecting its aggressive expansion and scaling efforts. In contrast, Alpine Immune Sciences experienced a more modest rise of approximately 870%, indicating a more measured growth strategy.
By 2023, Blueprint's SG&A expenses were nearly 13 times higher than Alpine's, underscoring its larger operational footprint. This analysis not only highlights the strategic differences between these two biotech players but also offers insights into how operational costs can shape a company's competitive edge in the industry.
Johnson & Johnson and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Amgen Inc. and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Blueprint Medicines Corporation
Blueprint Medicines Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Evotec SE